Austedo

The U.S. Food and Drug Administration approved Austedo in 2017 for the treament of involuntary movements associated with Huntington's Disease.

Go To Site


Xenazine

Xenazine was approved by the FDA in 2008 for controlling involutary movements associated with Huntington's disease.

Go To Site